Ivacaftor modulates Th17/Treg immune homeostasis to alleviate silicosis fibrosis in mice

SUN Xiaobo; CAI Qian; XIANG Guanhan; DU Xueting; WANG Kai; LIU Zhihong

doi:10.11836/JEOM24290

Volume 42 Issue 1

Jan. 2025

Turn off MathJax

Article Contents

Abstract

References

Supplements

Journal of Environmental and Occupational Medicine > 2025 > 42(1): 103-108. > DOI: 10.11836/JEOM24290

SUN Xiaobo, CAI Qian, XIANG Guanhan, DU Xueting, WANG Kai, LIU Zhihong. Ivacaftor modulates Th17/Treg immune homeostasis to alleviate silicosis fibrosis in mice[J]. Journal of Environmental and Occupational Medicine, 2025, 42(1): 103-108. DOI: 10.11836/JEOM24290

Citation:

PDF (1001 KB)

Ivacaftor modulates Th17/Treg immune homeostasis to alleviate silicosis fibrosis in mice

1.
Key Laboratory of Environmental Factors and Chronic Disease Control, School of Public Health, Ningxia Medical University, Yinchuan, Ningxia 750004, China
2.
Yinchuan Center for Disease Control and Prevention, Yinchuan, Ningxia 750004, China

Funds: This study was funded.

More Information

Corresponding author:
LIU Zhihong, E-mail: lzh_2580@sina.com
Received Date: July 07, 2024
Accepted Date: November 12, 2024

Graphical Abstract

Abstract

Abstract

Background
Long-term exposure to free silica particles can lead to lung tissue fibrosis, ultimately progressing to silicosis. There is an urgent need to develop specific drugs for silicosis treatment. Ivacaftor, a drug approved for treating cystic fibrosis, has shown potential for treating silicosis.
Objective
To investigate the effect of ivacaftor on alleviating pulmonary fibrosis in a silicosis mouse model, and to explore its mechanisms involving modulation of the T helper 17 (Th17)/regulatory T cell (Treg) immune response and related signaling pathways.
Methods
Forty-two male C57BL/6J mice (6-8 weeks old, weighing 18–22 g) were randomly divided into three groups: normal saline, silicosis model, and ivacaftor intervention groups. The treatment methods for each group were as follows: Mice received 50 μL of normal saline via tracheal instillation on days 1 and 7, and 50 μL of edible oil by oral gavage daily from days 14 to 56 in the normal saline group; mice received 50 μL of silica suspension (particle size: 0.5–10 μm, concentration: 50 mg·mL⁻¹) via tracheal instillation on days 1 and 7, and 50 μL of edible oil by oral gavage daily from days 14 to 56 in the silicosis model group; mice received 50 μL of silica suspension on days 1 and 7, and ivacaftor by oral gavage at a dose of 25 mg·kg⁻¹ (based on mouse body weight) daily from days 14 to 56 in the ivacaftor intervention group. Pathological evaluation of lung tissue was conducted after HE staining. The protein expression levels of active β-catenin, α-smooth muscle actin (α-SMA), and interleukin-17A (IL-17A) were measured by Western blotting (WB). Flow cytometry (FCM) was used to assess the relative expression levels of IL-17A and Foxp3 in lung tissue.
Results
After HE staining, the normal saline group showed normal alveolar structure, while the silicosis model group exhibited significant inflammation and fibrosis. The ivacaftor intervention group showed significantly reduced inflammation and fibrosis compared to the silicosis model group. The WB results showed that, compared with the normal saline group, the silicosis model group had significantly higher levels of α-SMA and IL-17A proteins (P<0.05). In contrast, the ivacaftor intervention group showed a significant reduction in active β-catenin and α-SMA expression, and a significant increment in IL-17A compared to the silicosis model group (P<0.05). The FCM results indicated that both the silicosis model group and the ivacaftor intervention group showed significantly increased levels of IL-17A and Foxp3 compared to the normal saline group (P<0.05). However, the ivacaftor intervention group further increased IL-17A expression and reduced Foxp3 expression compared to the silicosis model group (P<0.05).
Conclusion
Ivacaftor alleviates pulmonary fibrosis in a silicosis mouse model by promoting Th17 immune responses, inhibiting Treg immune responses, and downregulating the Wnt/β-catenin signaling pathway.
- silicosis,
- Th17 cell,
- Treg cell,
- ivacaftor,
- inflammation,
- fibrosis

FullText(HTML)

References (27)

References

[1]	YI X, HE Y, ZHANG Y, et al. Current status, trends, and predictions in the burden of silicosis in 204 countries and territories from 1990 to 2019[J]. Front Public Health, 2023, 11: 1216924. doi: 10.3389/fpubh.2023.1216924
[2]	RUPANI M P. A mixed-methods study on impact of silicosis on tuberculosis treatment outcomes and need for TB-silicosis collaborative activities in India[J]. Sci Rep, 2023, 13(1): 2785. doi: 10.1038/s41598-023-30012-4
[3]	LIU T T, SUN H F, HAN Y X, et al. The role of inflammation in silicosis[J]. Front Pharmacol, 2024, 15: 1362509. doi: 10.3389/fphar.2024.1362509
[4]	LIU F, LIU J, WENG D, et al. CD4+CD25+Foxp3+ regulatory T cells depletion may attenuate the development of silica-induced lung fibrosis in mice[J]. PLoS One, 2010, 5(11): e15404. doi: 10.1371/journal.pone.0015404
[5]	XIONG W, LIU Z G, XIONG L, et al. CD3⁺, CD4⁺, and CD8⁺ expression in cells in peripheral blood of silicosis patients and intervention effect of thymalfasin[J]. Ann Clin Lab Sci, 2019, 49(3): 368-371.
[6]	MA R, SUN D, WANG Y, et al. Cuproptosis-associated hub gene identification and immune cell infiltration patterns in silicosis[J]. Toxicology, 2024, 504: 153762. doi: 10.1016/j.tox.2024.153762
[7]	LIU Y, ZHAO N, XU Q, et al. MBL binding with AhR controls Th17 immunity in silicosis-associated lung inflammation and fibrosis[J]. J Inflamm Res, 2022, 15: 4315-4329. doi: 10.2147/JIR.S357453
[8]	THAKUR C, WOLFARTH M, SUN J, et al. Oncoprotein mdig contributes to silica-induced pulmonary fibrosis by altering balance between Th17 and Treg T cells[J]. Oncotarget, 2015, 6(6): 3722-3736. doi: 10.18632/oncotarget.2914
[9]	SONG L, WENG D, LIU F, et al. Tregs promote the differentiation of Th17 cells in silica-induced lung fibrosis in mice[J]. PloS One, 2012, 7(5): e37286. doi: 10.1371/journal.pone.0037286
[10]	DAI W, LIU F, LI C, et al. Blockade of Wnt/β-catenin pathway aggravated silica-induced lung inflammation through tregs regulation on Th immune responses[J]. Mediators Inflamm, 2016, 2016: 6235614.
[11]	JIA Y, WANG A, LIU L, et al. Chinese medicinal plant Polygonum cuspidatum ameliorates silicosis via suppressing the Wnt/β-catenin pathway[J]. Open Chem, 2022, 20(1): 1601-1611. doi: 10.1515/chem-2022-0266
[12]	WAINWRIGHT C E, ELBORN J S, RAMSEY B W. Lumacaftor-ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR[J]. N Engl J Med, 2015, 373(18): 220-231.
[13]	CARRASCO-HERNÁNDEZ L, QUINTANA-GALLEGO E, CALERO C, et al. Dysfunction in the cystic fibrosis transmembrane regulator in chronic obstructive pulmonary disease as a potential target for personalised medicine[J]. Biomedicines, 2021, 9(10): 1437. doi: 10.3390/biomedicines9101437
[14]	GRAEBER S Y, VITZTHUM C, PALLENBERG S T, et al. Effects of elexacaftor/tezacaftor/ivacaftor therapy on CFTR function in patients with cystic fibrosis and one or two F508del alleles[J]. Am J Respir Crit Care Med, 2022, 205(5): 540-549. doi: 10.1164/rccm.202110-2249OC
[15]	XIAO Q, KOUTSILIERI S, SISMANOGLOU D C, et al. CFTR reduces the proliferation of lung adenocarcinoma and is a strong predictor of survival in both smokers and non-smokers[J]. J Cancer Res Clin Oncol, 2022, 148(12): 3293-3302. doi: 10.1007/s00432-022-04106-x
[16]	BRUSCIA E M. The effects of elexafactor/tezafactor/ivacaftor beyond the epithelium: spurring macrophages to fight infections[J]. Eur Respir J, 2023, 61(4): 2300216. doi: 10.1183/13993003.00216-2023
[17]	蔡倩. 靶向Wnt/β-catenin和CFTR信号减轻小鼠矽肺纤维化病理发生的作用与分子机制研究[D]. 银川: 宁夏大学, 2022. CAI Q. The molecular mechanism of the mitigation of pathogenesis of silicosis in lungs of mice by targeting Wnt/β-catenin and CFTR signaling[D]. Yinchuan: Ningxia University, 2022.
[18]	WANG M, ZHANG Z, LIU J, et al. Gefitinib and fostamatinib target EGFR and SYK to attenuate silicosis: a multi-omics study with drug exploration[J]. Signal Transduct Target Ther, 2022, 7(1): 157. doi: 10.1038/s41392-022-00959-3
[19]	GONZÁLEZ C M, GONZÁLEZ A P, ALFONSO L G, et al. Silicosis in artificial quartz conglomerate workers[J]. Arch Bronconeumol (Engl Ed), 2019, 55(9): 459-464. doi: 10.1016/j.arbr.2019.07.001
[20]	PERIN F A, ALTMAYER S, NASCIMENTO D Z, et al. Long-term survival following unilateral lung transplantation for end-stage silicosis relative to idiopathic pulmonary fibrosis[J]. J Bras Pneumol, 2022, 48(2): e20210513.
[21]	LI T, YANG X, XU H, et al. Early identification, accurate diagnosis, and treatment of silicosis[J]. Can Respir J, 2022, 2022: 3769134.
[22]	HANDRA C M, GURZU I L, CHIRILA M, et al. Silicosis: new challenges from an old inflammatory and fibrotic disease[J]. Front Biosci (Landmark Ed), 2023, 28(5): 96. doi: 10.31083/j.fbl2805096
[23]	TANG M, YANG Z, LIU J, et al. Combined intervention with N-acetylcysteine and desipramine alleviated silicosis development by regulating the Nrf2/HO-1 and ASMase/ceramide signaling pathways[J]. Ecotoxicol Environ Saf, 2022, 242: 113914. doi: 10.1016/j.ecoenv.2022.113914
[24]	CHENG L, JIAO Y, JIANG W, et al. IL-33 deficiency attenuates lung inflammation by inducing Th17 response and impacting the Th17/Treg balance in LPS-induced ARDS mice via dendritic cells[J]. J Immunol Res, 2022, 2022: 9543083.
[25]	SONG J, LIU Y, GUO Y, et al. Therapeutic effects of tetrandrine in inflammatory diseases: a comprehensive review[J]. Inflammopharmacology, 2024, 32(3): 1743-1757. doi: 10.1007/s10787-024-01452-9
[26]	LI C, DU S, LU Y, et al. Blocking the 4-1BB pathway ameliorates crystalline silica-induced lung inflammation and fibrosis in mice[J]. Theranostics, 2016, 6(12): 2052-2067. doi: 10.7150/thno.16180
[27]	XIONG S, GUO R, YANG Z, et al. Treg depletion attenuates irradiation-induced pulmonary fibrosis by reducing fibrocyte accumulation, inducing Th17 response, and shifting IFN-γ, IL-12/IL-4, IL-5 balance[J]. Immunobiology, 2015, 220(11): 1284-1291. doi: 10.1016/j.imbio.2015.07.001